Get the Stockscreener App
1.915
1.79%
-0.035
After Hours:
1.94
0.025
+1.31%
Casi Pharmaceuticals Inc stock is traded at $1.915, with a volume of 3,155.
It is down -1.79% in the last 24 hours and down -8.37% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$1.95
Open:
$1.93
24h Volume:
3,155
Relative Volume:
0.30
Market Cap:
$32.22M
Revenue:
$22.06M
Net Income/Loss:
$-30.94M
P/E Ratio:
-0.8549
EPS:
-2.24
Net Cash Flow:
$-26.70M
1W Performance:
-7.93%
1M Performance:
-8.37%
6M Performance:
-67.87%
1Y Performance:
-31.48%
1-Day Range:
$1.915
$1.94
1-Week Range:
$1.915
$2.08
52-Week Range:
$1.88
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.915 | 32.22M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - ACCESS Newswire
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
CASI Pharmaceuticals, Inc.Ordinary Shares (NQ: CASI - FinancialContent
Brokers Issue Forecasts for CASI Q1 Earnings - Defense World
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
HC Wainwright Has Lowered Expectations for CASI Pharmaceuticals (NASDAQ:CASI) Stock Price - Defense World
CASI stock touches 52-week low at $1.88 amid market challenges - Investing.com
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech - TipRanks
CASI receives updated buyout offer for China operations - The Pharma Letter
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
CASI Pharma stock hits 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks
Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics - marketscreener.com
CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations - TipRanks
CASI Pharmaceuticals receives buyout proposal from CEO - Investing.com
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - ACCESS Newswire
CASI Pharma's CEO Makes Strategic $20M Bid for Entire China BusinessKey Pipeline Assets Included - Stock Titan
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Yahoo
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 15.0% - Defense World
CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
CASI Delivers Record Q4 Growth: FDA Clearance Powers Next-Gen Treatment Pipeline - Stock Titan
CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com - Defense World
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com - The AM Reporter
CASI Pharma stock hits 52-week low at $2.04 amid market challenges - Investing.com
CASI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year - Yahoo Finance
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):